TX-VINCENT-LOUIS-MOGAS
3.5.2024 19:31:27 CEST | Business Wire | Press release
MOGAS mourns the death of their beloved chairman and founder Vincent Louis Mogas, who died on May 2, 2024 in Houston, Texas. Louis spent his life building a valve manufacturing business and a company culture that stood for goodness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240503919754/en/
V. Louis Mogas, Founder and Chairman of MOGAS Industries (1939 - 2024) (Photo: MOGAS Industries Inc.)
MOGAS Industries was formed in May 1973 when Louis Mogas purchased a small machine shop in Houston. He soon acquired the rights to service and manufacture ball valves from Cameron Iron Works. Under Louis' leadership, the Company studied valve failures and established an R&D department that customized valves for specific applications. Since 2000, MOGAS has established sales and service offices in Australia, China, Europe, Canada, South America, Middle East and India.
Early on, Louis Mogas introduced business behaviors that became the foundation of the Company's core values--everyone is the CEO of something, make work fun, do what's right--to name a few. His belief that work can be fun and honorable, and that there is one team at MOGAS drive the Company's business principles today.
While Louis received many Company awards, including The Inc. 500 Fastest Growing Private Companies, multiple Best Companies to Work For in Texas, vendor excellence, Texas Family Large Business of the Year Finalist, and Best Quality Product, he was most proud of his and his family's philanthropy, and of employee fund raising and volunteerism contributions. These include Ronald McDonald House Houston, The Periwinkle Foundation, Camp for All, National Multiple Sclerosis Association, and several Houston district schools. In 2017 Louis Mogas was honored as a distinguished alumni at Texas A&M University, Kingsville for the creation of the Mogas Family Perseverance Scholarship Endowment. MOGAS Industries also awards scholarships and educational grants to employees and their children, and mentors summer hire interns.
The family of Louis Mogas, the MOGAS Executive Leadership Team and our employees worldwide are mourning the loss of a tremendous man whose leadership was only matched by his passion and fervor for life and serving others. We all carry the lessons that Louis shared with us in our hearts and we will continue to share his legacy to the world through our work and in our lives.
"Always live out your values in your work, so that when you drive home at the end of each day, you can feel proud of yourself." Louis Mogas
ABOUT MOGAS INDUSTRIES, INC.
MOGAS Industries is the most trusted severe service technology company offering severe service valves, surface engineering/coating, modular process units, and aftermarket support. Our world-renowned, application-specific products and service are best-in-class for critical applications in power, mining, oil & gas, refining, chemical/petrochemical, pulp & paper and specialty industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503919754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release
Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release
International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom